ACL Digital Acquires Symbiance

Syneos Health Acquires Synteract from Amulet Capital Partners

December 10, 2020

Healthcare Services

Syneos Health (NASDAQ: SYNH) has completed the acquisition of Synteract, a full-service contract research organization (CRO) focused on emerging biopharma. The seller was Amulet Capital Partners, which had previously built Synteract through organic investment and add-on acquisitions.

ACL Digital Acquires VOLANSYS

April 28, 2022

Engineering Services

ACL Digital, an ALTEN Group company, has acquired VOLANSYS to expand its product engineering, digital transformation and IoT capabilities. The deal strengthens ACL Digital's end-to-end IoT and product realization services, enabling accelerated development from concept to manufacturing across multiple industry verticals.

NAMSA Acquires Syntactx

January 5, 2021

Healthcare Services

NAMSA, a medical device–focused contract research organization (and portfolio company of ArchiMed), has acquired New York–based CRO Syntactx. The add-on purchase expands NAMSA’s clinical research, electronic data capture (EDC), core lab imaging, safety and cardiovascular regulatory consulting capabilities to better serve global medtech sponsors.

Altasciences Acquires Sinclair Research

January 4, 2022

Healthcare Services

Altasciences completed the acquisition of Sinclair Research, a Midwest-based preclinical CRO, expanding its U.S. preclinical footprint and adding capacity and toxicology expertise. The deal brings Sinclair’s over-80-animal-room capabilities into Altasciences’ integrated CRO/CDMO platform to better support biopharmaceutical, animal health, and medical device development programs.

Hippocratic AI Acquires Grove AI

January 12, 2026

AI & Machine Learning

Hippocratic AI has acquired Grove AI to accelerate its Life Sciences Division, integrating Grove AI's agentic AI platform and team to expand clinical engagement and trial operations capabilities. The move complements Hippocratic AI's Polaris safety architecture and follows its recent $126M Series C, while the company also launched a Life Sciences Executive Advisory Council and a strategic collaboration with BCG.

Avance Clinical Acquires C3 Research Associates to Expand into North America

September 6, 2022

Healthcare Services

Avance Clinical, a PE-backed Australian CRO, has acquired North American CRO partner C3 Research Associates to expand its later‑phase clinical trial capabilities and establish a US presence. Backed by private equity firm The Riverside Company, Avance will integrate C3 into its GlobalReady model and invest in growing its North American team to support biotechs transitioning from early‑phase studies in Australia/New Zealand to later phases in the US.